China’s NMPA Fast-Tracks Gyre Therapeutics’ Hydronidone (F351)
China’s NMPA has granted priority review to Gyre Therapeutics’ NDA for Hydronidone (F351) for chronic hepatitis B liver fibrosis.
/ 3 items
#GYRE↓
Gyre Therapeutics Strikes $300M All-Stock Deal to Acquire Cullgen, Bolstering TPD Pipeline for Cancer and Pain
Gyre Therapeutics agrees to acquire Cullgen in $300M all-stock deal, gaining TPD/DAC platform for oncology, pain, and inflammatory diseases. Deal to close Q2 2026 after Cullgen ends Pulmatrix merger.
Gyre Therapeutics Gains on China Drug Approval Pathway
Gyre Therapeutics (GYRE) stock jumps 14% after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment.